Featured Press Releases

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Viking Therapeutics and CordenPharma Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables, and Oral Formulations

Viking Therapeutics and CordenPharma Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables, and Oral Formulations

  • 11 Mar 2025

CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in...

Supporting the lab of the future, MilliporeSigma partners with Opentrons Labworks, Inc

Supporting the lab of the future, MilliporeSigma partners with Opentrons Labworks, Inc

Spyre Therapeutics Announces Inducement Award Grants

Spyre Therapeutics Announces Inducement Award Grants

Alafair Biosciences Announces Enrollment of First Patient in Multi-Center Study Testing VersaWrap® Tendon Protector for Achilles Repair

Alafair Biosciences Announces Enrollment of First Patient in Multi-Center Study Testing VersaWrap® Tendon Protector for Achilles Repair

ProductLife Group Appoints Dr. James Burt as CEO

ProductLife Group Appoints Dr. James Burt as CEO

Strong Performance Across More Than 200 Customer Audits Highlighted by Piramal Pharma Solutions

Strong Performance Across More Than 200 Customer Audits Highlighted by Piramal Pharma Solutions

  • Piramal Pharma Solutions
  • 22 Jun 2026
Cryo-EM Collaboration Between Gandeeva and Zymeworks Speeds Antibody Drug Discovery

Cryo-EM Collaboration Between Gandeeva and Zymeworks Speeds Antibody Drug Discovery

  • Gandeeva Therapeutics Inc.
  • 18 Jun 2026
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

  • Merck & Co., Inc.
  • 18 Jun 2026
Avenacy Announces the U.S. Launch of Bortezomib for Injection

Avenacy Announces the U.S. Launch of Bortezomib for Injection

  • Avenacy
  • 18 Jun 2026
WISE Closes Oversubscribed €30 Million Series D Financing Round with ENEA Tech and Biomedical Joining as Strategic Investor

WISE Closes Oversubscribed €30 Million Series D Financing Round with ENEA Tech and Biomedical Joining as Strategic Investor

  • WISE S.p.A.
  • 17 Jun 2026
Rugiet Launched Physician-Prescribed Peptide and Longevity Therapies, Setting a New Standard in Performance Medicine

Rugiet Launched Physician-Prescribed Peptide and Longevity Therapies, Setting a New Standard in Performance Medicine

  • Rugiet
  • 17 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.